Highlights from Selected Cardiovascular Disease Prevention Studies Presented at the 2019 European Society of Cardiology Congress

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

(2019) Matthew T. Roe et al.   CIRCULATION

Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity

(2019) Ali Aminian et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS)

(2019) Konstantinos C. Koskinas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

(2019) Salim S. Virani et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study

(2019) Salim Yusuf et al.   LANCET

Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease

(2019) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial

(2019) Jon-David Schwalm et al.   LANCET

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

(2018) J Michael Gaziano et al.   LANCET

Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

(2018) John J. McNeil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes

(2017) Philip R. Schauer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both

(2015) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial

(2015) Geltrude Mingrone et al.   LANCET

Clinical Effect of Naturally Random Allocation to Lower Systolic Blood Pressure Beginning Before the Development of Hypertension

(2014) Brian A. Ference et al.   HYPERTENSION

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

(2013) David C. Goff et al.   CIRCULATION

General Cardiovascular Risk Profile for Use in Primary Care

(2008) Ralph B. D’Agostino et al.   CIRCULATION